Brought to you by 
OrthoLogic acquires Chrysalis BioTechnology
06 Aug 2004
Executive Summary
OrthoLogic Corp. (musculoskeletal healing) has agreed to purchase all the assets and intellectual property of the orthobiologics company Chrysalis BioTechnology, from which OLC licensed its key tissue-repair platform technology, Chrysalin, in 1998.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Includes Earnout
- Intra-Biotech Deal
- Payment Includes Cash
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
OrthoLogic acquires Chrysalis BioTechnology
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice